Cannabis Science Chief Operating Officer Dr. Moe Afaneh, Pharm D., MBA, NRCC, Confirms Newest Cannabis Science Brand Product ...
February 24 2012 - 1:55PM
Business Wire
Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S.
biotech company developing pharmaceutical cannabis (marijuana)
products, is pleased to announce Dr. Moe Afaneh, Pharm D., MBA,
NRCC, RNC has identified the first four Cannabis Science Brand
products as the newest line of Cannabis Science Brand of Products.
Dr. Afaneh expects to have a full report next week with the new
product offering launch plan including nationwide manufacturing and
distribution.
The Cannabis Science Executive Team is finalizing negotiations
for the manufacturing and national distribution or this new product
line. The commercialization process is well underway including
securing manufacturing partners that have the resources to support
our national distribution and retail outlets such as pharmacies
through to grocery outlets and other multi-national retail outlets.
Negotiations will actively continue when the first prototypes are
received by Cannabis Science to be review by various nationwide
product distributors eagerly looking to release this new line of
Cannabis Science Brand of Products.
This new product launch is the first mandate for our newly
appointed Chief Operations Officer Dr. Afaneh. He has made great
progress in the short time since he has begun, and is now ahead of
schedule for this launch. Dr. Afaneh’s mandate includes improving
the overall efficiency and quality of Cannabis Science’s national
pharmaceutical operations and penetrating additional national
markets with new developed high quality Cannabis Science brand
products. Dr. Afaneh and the Cannabis Science team are working to
enter the over-the-counter (OTC) market in 2012, with
non-psychoactive nutraceuticals, as well as to enter the dispensary
market with both psychoactive and non-psychoactive cannabis-based
treatments.
Dr. Robert Melamede, President of Cannabis Science stated, “Dr.
Moe is ahead of our projections and we are very proud. The retail
availability of these products should increase revenue and that’s
great for Cannabis Science and our shareholders. I am confident
that we will realize our financial plans and goals that should
bring Cannabis Science to profitability in 2014. I look forward to
using many of these products for myself and my family in the near
future.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The Company works
with world authorities on phytocannabinoid science targeting
critical illnesses, and adheres to scientific methodologies to
develop, produce and commercialize phytocannabinoid-based
pharmaceutical products. In sum, we are dedicated to the creation
of cannabis-based medicines, both with and without psychoactive
properties, to treat disease and the symptoms of disease, as well
as for general health maintenance.
Forward Looking Statements; This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing works such as "anticipate," "seek,"
intend," "believe," "plan," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science, Inc.
does not undertake any duty nor does it intend to update the
results of these forward-looking statements.